CN118176182A - 用于治疗激酶依赖性病症的化合物 - Google Patents

用于治疗激酶依赖性病症的化合物 Download PDF

Info

Publication number
CN118176182A
CN118176182A CN202280073218.2A CN202280073218A CN118176182A CN 118176182 A CN118176182 A CN 118176182A CN 202280073218 A CN202280073218 A CN 202280073218A CN 118176182 A CN118176182 A CN 118176182A
Authority
CN
China
Prior art keywords
less
compound
formula
fluoroaniline
aminophenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280073218.2A
Other languages
English (en)
Chinese (zh)
Inventor
K·沙
F·德莫林
S·释迦
王勇
W·徐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CN118176182A publication Critical patent/CN118176182A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202280073218.2A 2021-11-03 2022-11-03 用于治疗激酶依赖性病症的化合物 Pending CN118176182A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163275255P 2021-11-03 2021-11-03
US63/275,255 2021-11-03
PCT/US2022/048770 WO2023081253A1 (en) 2021-11-03 2022-11-03 Compounds for the treatment of kinase-dependent disorders

Publications (1)

Publication Number Publication Date
CN118176182A true CN118176182A (zh) 2024-06-11

Family

ID=84462825

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280073218.2A Pending CN118176182A (zh) 2021-11-03 2022-11-03 用于治疗激酶依赖性病症的化合物

Country Status (9)

Country Link
US (1) US20250051284A1 (https=)
EP (1) EP4426678A1 (https=)
JP (1) JP2024539721A (https=)
CN (1) CN118176182A (https=)
AR (1) AR127561A1 (https=)
AU (1) AU2022383160A1 (https=)
CA (1) CA3235602A1 (https=)
TW (1) TW202334090A (https=)
WO (1) WO2023081253A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402114A (zh) * 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402114A (zh) * 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
KR102828472B1 (ko) * 2018-12-13 2025-07-03 엑셀리시스, 인코포레이티드 키나아제 억제제의 결정질 형태 및 염 형태
MX2021014773A (es) * 2019-06-03 2022-01-18 Exelixis Inc Formas de sales cristalinas de un inhibidor de cinasas.
CN115461328B (zh) * 2020-04-30 2025-11-07 埃克塞里艾克西斯公司 用于制备激酶抑制剂的方法
JP2023548855A (ja) * 2020-11-05 2023-11-21 エグゼリクシス， インコーポレイテッド キナーゼ阻害剤の医薬組成物

Also Published As

Publication number Publication date
AR127561A1 (es) 2024-02-07
WO2023081253A1 (en) 2023-05-11
CA3235602A1 (en) 2023-05-11
US20250051284A1 (en) 2025-02-13
AU2022383160A1 (en) 2024-05-02
JP2024539721A (ja) 2024-10-29
EP4426678A1 (en) 2024-09-11
TW202334090A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
US11123338B2 (en) C-met modulator pharmaceutical compositions
CN101337933B (zh) 喹啉羧酰胺的甲磺酸盐的结晶(a)及其制备方法
KR20080015888A (ko) 카르베딜올
KR20190049907A (ko) 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US11820772B2 (en) Polymorphs of the hydrochloride salt of linaprazan glurate
WO2024248083A1 (ja) キノリン置換化合物の結晶
CN118176182A (zh) 用于治疗激酶依赖性病症的化合物
WO2015034031A1 (ja) 新規な結晶性アリールアルキルアミン化合物およびその製造方法
TW201008935A (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
JP5829741B2 (ja) 新規な結晶性アリールアルキルアミン化合物およびその製造方法
JP5681841B1 (ja) 新規な結晶性アリールアルキルアミン化合物およびその製造方法
CN115803329A (zh) 八氢噻吩并喹啉化合物的琥珀酸盐及其晶体
WO2024201244A1 (en) Solid state forms of bavdegalutamide and process for preparation thereof
WO2026095022A1 (ja) キノリン置換化合物の結晶
EP4673223A1 (en) Solid state forms of anlotinib and process for preparation thereof
WO2022253261A1 (zh) Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
IL322047A (en) Solid forms of dalgocitinib and processes for their preparation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination